$X4 Pharmaceuticals (XFOR.US)$ X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

$X4 Pharmaceuticals (XFOR.US)$ Item 8.01 Other Events.
As previously disclosed on a Current Report on Form 8-K filed by X4 Pharmaceuticals, Inc. (the “Company”), on August 13, 2024, the Company received a deficiency letter (the “Nasdaq Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 32 consecutive business days, the closing bid price of the Company’s shares of common stock, $0.001 par value per share (“Common Stock”), has not been maint...

$X4 Pharmaceuticals (XFOR.US)$
Reduced TAM to about 500 patients in the US (still probably an over-estimate given its rarity) recently. 23-27% of sales face exposure to Rx tariffs. $112M C&E acts as an immediate buffer. Sales targets will likely be lower than projections.

$X4 Pharmaceuticals (XFOR.US)$ X4 Pharmaceuticals And Taiba Rare Partner For XOLREMDI Distribution In Middle East Countries
X4 Pharmaceuticals (XFOR) and taiba rare, a healthcare company, announced a strategic exclusive partnership for the distribution and commercialization of XOLREMDI in select Middle East countries, pending regulatory approvals.

$X4 Pharmaceuticals (XFOR.US)$ Reuters
5 mins ago
X4 Pharmaceuticals and Taiba Rare Announce Exclusive Agreement for the Distribution and Commercialization of Xolremdi® (Mavorixafor) in Whim Syndrome in Select Middle East Countries

$X4 Pharmaceuticals (XFOR.US)$
Groundbreaking WHIM Syndrome Drug Enters Middle East: Inside X4's Strategic Distribution Deal

$X4 Pharmaceuticals (XFOR.US)$ X4 Pharmaceuticals and Taiba Rare Announce Exclusive Agreement for the Distribution and Commercialization of Xolremdi® (Mavorixafor) in Whim Syndrome in Select Middle East Countries

$X4 Pharmaceuticals (XFOR.US)$ 😒 🤔 👁

$X4 Pharmaceuticals (XFOR.US)$ No more shares avail at .47?